Welcome to our dedicated page for Rhinebeck Bancorp SEC filings (Ticker: RBKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rhinebeck Bancorp, Inc. filings document the public-company disclosures of a Maryland bank holding company for Rhinebeck Bank and its common stock listed on Nasdaq under RBKB. Form 8-K reports provide operating and financial results, including net interest income, expenses, credit-loss provisions and other bank performance measures.
Proxy materials cover annual meeting voting matters, board composition, governance and executive compensation. Registration statements and amendments address securities offering disclosures, the Rhinebeck Bank 401(k) Plan, capital structure and related risk factors for the company, Rhinebeck Bancorp, MHC and the bank.
Rhinebeck Bancorp, Inc. director Steven E. Howell reported a compensation-related stock award rather than an open-market trade. He received 1,624 shares of common stock at no cost, increasing his directly held common stock to 6,624 shares. These shares are restricted and will vest in three equal annual installments beginning on May 26, 2027. Howell also reports indirect ownership of 5,000 common shares through a 401(k) plan and holds fully vested stock options covering 16,365 shares of common stock at an exercise price of $6.57 per share, expiring in 2030.
Rhinebeck Bancorp, Inc. Chief Credit & Risk Officer James T. McCardle III received a grant of 8,182 shares of Common Stock at no cost as a stock award, increasing his direct holdings to 11,762 shares. A footnote states these restricted shares vest at a rate of 33 1/3% per year commencing on May 26, 2027. The filing also reports indirect holdings of 3,705 shares through an ESOP and 9,858 shares through a 401(k), and shows fully vested stock options covering 28,000 shares of Common Stock at an exercise price of $6.57 per share expiring August 25, 2030.
Rhinebeck Bancorp, Inc. Chief Operating Officer Jamie J. Bloom reported a compensation-related stock grant. Bloom received 10,487 shares of Common Stock at $0.00 per share as a grant or award, bringing direct Common Stock holdings to 10,522 shares after the transaction. A footnote states these are restricted shares that vest in equal installments of 33 1/3% per year starting on May 26, 2027. The filing also shows indirect holdings of 3,999 Common shares through an ESOP, 1,410 Common shares through a 401(k), and stock options on 28,000 underlying Common shares that are fully vested with a $6.57 exercise price and an expiration date of August 25, 2030.
Rhinebeck Bancorp, Inc. director Nancy Koskey Patzwahl reported a compensation-related stock grant. She acquired 1,624 shares of common stock as an award at a stated price of $0.00 per share, bringing her directly held position to 1,624 shares.
The award is in the form of restricted stock that vests over time. According to the disclosure, these shares vest at a rate of 33 1/3% per year, commencing on May 26, 2027, meaning the grant becomes fully vested over three years starting from that date.
Rhinebeck Bancorp director Sharon McGinnis reported an acquisition of 1,624 shares of Common Stock through a grant or award with a stated price of $0.00 per share. These are restricted shares that vest in thirds, with 33 1/3% vesting each year starting on May 26, 2027. After this award, McGinnis directly holds 1,624 shares, reflecting a routine compensation-related equity grant rather than an open-market purchase.
Rhinebeck Bancorp director Suzanne Loughlin reported a routine equity compensation grant and her existing option holdings. She received 1,624 shares of Common Stock as a grant at $0.00 per share, increasing her direct holdings to 24,559 shares of Common Stock.
The granted shares are restricted stock that will vest in three equal annual installments of 33 1/3% starting on May 26, 2027. She also holds fully vested stock options covering 16,365 shares of Common Stock at an exercise price of $6.57 per share, expiring on August 25, 2030.
Rhinebeck Bancorp, Inc. director Shannon Martin LaFrance reported an equity compensation award on common stock. LaFrance received 1,624 shares of restricted common stock at a stated price of $0.00 per share, classified as a grant or award rather than an open‑market purchase. These restricted shares vest in equal installments of 33 1/3% per year starting on May 26, 2027. Following this award, LaFrance directly holds 23,352 shares of common stock. The filing also shows fully vested stock options covering 16,365 underlying common shares with an exercise price of $6.57 per share that expire on August 25, 2030, indicating an additional derivative equity position.
Rhinebeck Bancorp, Inc. senior vice president and chief accounting officer Phillip Lekanides received a grant of 3,410 shares of common stock at no cost as a restricted stock award. These shares vest at a rate of 33 1/3% per year starting on May 26, 2027.
After this award, Lekanides directly holds 5,715 common shares. He also has indirect holdings of 1,852 shares through an ESOP and 3,744 shares through a 401(k). In addition, he holds fully vested stock options covering 1,500 shares of common stock at an exercise price of $6.57 per share, expiring on August 25, 2030. Other entries reflect holdings not required to be reported as Section 16 transactions.
Rhinebeck Bancorp director Freddimir Garcia reported a stock-based compensation grant. He received 1,624 shares of restricted Common Stock at no cash cost, increasing his direct common share holdings to 4,798.
The restricted shares vest in three equal installments of 33 1/3% per year starting on May 26, 2027. Garcia also holds fully vested stock options covering 16,365 shares of Common Stock with an exercise price of $6.57 per share, expiring on August 25, 2030.
Rhinebeck Bancorp, Inc. director Christopher W. Chestney reported an award of 1,624 shares of Common Stock as a grant or other acquisition at $0.00 per share, bringing his directly held common shares to 22,135.
The granted shares are restricted stock that vest at a rate of 33 1/3% per year starting on May 26, 2027. He also holds fully vested stock options covering 16,365 shares of Common Stock at an exercise price of $6.57 per share, expiring on August 25, 2030. In addition, Form 4 reflects indirect holdings of 1,000 shares each held by his daughter, son, and spouse.